As of 2025-05-16, the EV/EBITDA ratio of Provectus Biopharmaceuticals Inc (PVCT) is -9.64. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PVCT's latest enterprise value is 37.95 mil USD. PVCT's TTM EBITDA according to its financial statements is -3.94 mil USD. Dividing these 2 quantities gives us the above PVCT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.9x - 7.1x | 7.0x |
| Forward P/E multiples | 4.3x - 7.8x | 6.0x |
| Fair Price | (0.07) - (0.07) | (0.07) |
| Upside | -185.6% - -187.8% | -181.4% |
| Date | EV/EBITDA |
| 2025-02-28 | -12.08 |
| 2025-02-27 | -12.09 |
| 2025-02-26 | -12.11 |
| 2025-02-25 | -11.52 |
| 2025-02-24 | -11.93 |
| 2025-02-21 | -12.02 |
| 2025-02-20 | -12.32 |
| 2025-02-19 | -12.22 |
| 2025-02-18 | -11.92 |
| 2025-02-14 | -11.85 |
| 2025-02-13 | -11.73 |
| 2025-02-12 | -11.78 |
| 2025-02-11 | -11.69 |
| 2025-02-10 | -11.88 |
| 2025-02-07 | -10.97 |
| 2025-02-06 | -11.05 |
| 2025-02-05 | -11.24 |
| 2025-02-04 | -11.18 |
| 2025-02-03 | -11.42 |
| 2025-01-31 | -11.99 |
| 2025-01-30 | -12.41 |
| 2025-01-29 | -12.79 |
| 2025-01-28 | -13.25 |
| 2025-01-27 | -12.98 |
| 2025-01-24 | -13.14 |
| 2025-01-23 | -13.31 |
| 2025-01-22 | -12.86 |
| 2025-01-21 | -12.66 |
| 2025-01-17 | -12.92 |
| 2025-01-16 | -13.22 |
| 2025-01-15 | -13.09 |
| 2025-01-14 | -13.24 |
| 2025-01-13 | -12.96 |
| 2025-01-10 | -12.71 |
| 2025-01-08 | -12.69 |
| 2025-01-07 | -12.90 |
| 2025-01-06 | -13.53 |
| 2025-01-03 | -13.53 |
| 2025-01-02 | -13.57 |
| 2024-12-31 | -13.54 |
| 2024-12-30 | -13.73 |
| 2024-12-27 | -13.73 |
| 2024-12-26 | -13.79 |
| 2024-12-24 | -13.50 |
| 2024-12-23 | -13.95 |
| 2024-12-20 | -13.53 |
| 2024-12-19 | -14.53 |
| 2024-12-18 | -14.57 |
| 2024-12-17 | -14.69 |
| 2024-12-16 | -14.79 |